|
Catalogue
Number
|
Product
|
Order number / Unit
|
|
|
9925
|
DCFPyL reference standard
|
9925.0005: 5 mg per vial
9925.0010: 10 mg per vial
Please inquire for customized
filling and bulk quantities.
|
|
|
Reference standard for [18F]DCFPyL
2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid
|
|
|
Research Chemical
|
|
|
The tracer [18F]DCFPyL is patent-protected in some countries, please consider to inquire for PSMA-1007 compounds (ID 9943, 99433) instead, that are provided by ABX under exclusive licence.
|
|
|
Molar Mass: 442.40
|
|
|
C18H23FN4O8
|
|
|
[1423758-00-2]
|
|
|
|
|
|
Colourless to off-white solid packaged in dark glass screw cap vials.
|
|
|
|
|
|
|
|
|
Purity: ≥ 95 %
|
|
|
Certificates:
CoA; 1H and 19F NMR spectra (identity); HPLC (purity)
|
|
|
Chemical Name:
2-(3-{1-carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid
|
|
|
Synonymes:
[18F]DCFPyL standard; 2-(3-{1-Carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid
|
|
|
Literature:
Chen Y. et al. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. Clin. Cancer. Res. 2011, 17, 7645-7653.
|
|
|
Szabo Z. et al. Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol. Imaging Biol. 2015, 17, 565-574.
|
|
|
Rowe S.P. et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann. Nucl. Med. 2015, 29, 877-882.
|
|
|
Rowe S.P. et al. Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma. Clin. Nucl. Med. 2016, 41, 83-85.
|
|
|
Dietlein M. et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol. Imaging Biol. 2015, 17, 575-584.
|
|
|
date of product catalogue issue:
10 May 2017
|